AzTrials
AzTrials

MeaslesPhase 4NCT00168545

Immunology of Non-specific Effects of Vaccine

A Phase 4 study testing Measles vaccine in people with Measles and Diphtheria, run by Bandim Health Project at 1 site in Guinea-Bissau.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

OBJECTIVES General: To investigate the immunological background for the non-specific effects of diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality Specific: Examine the cytokine responses and possible association with morbidity in a study of DTP vaccinated children who will be randomised to… Read more about this study

Who is it for?
Ages 4 to 9 monthsHealthy volunteers can take part
Conditions the study is for
Measles, Diphtheria, Tetanus
What is being tested?
Measles vaccine
Type of treatment
Vaccines
How many people
400 participants
Where
1 siteGuinea-Bissau
Study dates
Jan 2006to Jan 2007
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 9 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Inclusion Criteria: A sub-cohort of children participating in the study "MEASLES VACCINATION IN GUINEA-BISSAU. STRATEGIES TO REDUCE DISEASE BURDEN AND IMPROVE CHILD SURVIVAL", protocol ID: RUF-91134-2601-Twodose2.

Exclusion Criteria: Severe illness

Trial locations and contacts

1 site in 1 country.

Guinea-Bissau1 site
  • Bandim Health Project

    Bissau, Apartado 861, 1004 Bissau Codex

Other trials in Guinea-Bissau

About this study

Official title: Non-specific Effects of Vaccines - In Search of the Immunological Background

OBJECTIVES

  • General: To investigate the immunological background for the non-specific effects of diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality
  • Specific: Examine the cytokine responses and possible association with morbidity in a study of DTP vaccinated children who will be randomised to receive a measles vaccine or no vaccine at 4½ months of age. (All children will receive a measles vaccine at 9 months of age)
Read the detailed description

Non-specific effects of vaccines The idea of vaccines having non-specific effects was first proposed in 1991 from a study in Senegal, West Africa. It was discovered that children receiving high-titre measles vaccine (HT) at 6 months of age had higher mortality than children who received the standard titre measles vaccine (STD) at 9 months of age. The difference was found only for girls. A study from Haiti confirmed the effect. Since children vaccinated with HT had lower mortality than their equivalents who had not received any measles vaccine, the difference in mortality between recipients of HT vaccine and STD vaccine was explained by a non-specific beneficial effect of the STD measles vaccine rather than a harmful effect of the HT vaccine. The non-specific beneficial effect of STD measles vaccine on child mortality has been reconfirmed in many data-sets.

Also the BCG vaccine is associated with striking effects on child mortality reducing mortality by about 50%. Further, among BCG vaccinated children, having a BCG scar or a positive tuberculin reaction was associated with about 55% lower mortality in the following 12 months than among children who had a negative tuberculin reaction or who did not have a BCG scar.

The effect of OPV is difficult to separate from the effects of BCG and DTP vaccines since OPV is normally given together with these vaccines. There have, though, been some periods without DTP in Bissau due to global shortage of vaccines, and we have compared the case fatality at the hospital for children who received only OPV and children who received both the prescribed OPV and DTP. Children having received OPV had 3-fold lower mortality than children having received both vaccines. Data from an OPV vaccination campaign that took place in Guinea-Bissau also suggested a non-specific beneficial effect for the recipients. Further, studies from Chile and the Soviet Union have suggested that OPV had a beneficial effect on mortality and morbidity.

In contrast, DTP, HBV and inactivated polio vaccine (IPV) seem to exert a non-specific detrimental effect on child mortality, although the findings on DTP were considered controversial by a recent review. Current studies indicate that the negative effect of DTP may be neutralized by a subsequent measles vaccination. It is striking that all the vaccines with a non-specific beneficial effect are live, whereas the vaccines with an apparently harmful effect are killed. Results from animal studies have shown that attenuated live vaccines tend to induce a Th1 response and offer better protection against severe disease than the corresponding inactivated vaccines, which tend to induce a Th2 response. So far, very few studies have examined whether these effects differ between male and female animals. One study reported that BCG-vaccinated female mice were better protected against malaria parasites than male mice (31). There is therefore an urgent need to conduct studies that can help uncover the immunology behind the non-specific effects.

Sex-specific effects All epidemiological studies carried out so far confirms the observation that non-specific effects are sex-specific. Live vaccines (measles, BCG, OPV) have a beneficial effect that is particularly good for girls whereas inactivated vaccines (DTP, HBV, IPV) have a negative effect for girls. To date, there are no immunological studies which have examined whether routine vaccines affect the immune system differently for boys and girls.

We thus propose to study, in a randomised controlled trial of measles vaccination taking place in Guinea-Bissau, the immunology of non-specific effects of vaccination, and their interaction with sex. Specifically, among children who have received the 3 recommended doses of DTP, we will be able to compare the cytokine and antibody profiles of children who receive an early dose of measles vaccine at 4½ months of age with children who receive no additional vaccine at this age.

Being tested
Measles vaccine
Keywords
Non-specific effects of vaccines, Immunology, Cytokines, Infant mortality, Child mortality, Mortality, Morbidity, Diphtheria-tetanus-pertussis vaccine, Measles vaccine, Measles, Immunisation, Low income country, Guinea-Bissau, Bandim Health Project, Immunology of measles and DTP vaccination
Medical subject headings
Measles, Diphtheria, Tetanus, Whooping Cough, Infant Death

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Measles vaccineBiological

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cytokine levels in the randomised groups

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2005 (estimated)
  2. Study startJan 2006
  3. Study completionJan 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00168545
Sponsor's protocol ID
NOVO-2624-Twodose2_immunology
Other IDs
NOVO-2624, LÆGEVIDENSKABENS FREMME-2623
Status last verified
Sep 2006
First submitted
9 Sep 2005
Last updated
22 Sep 2011
Results posted
No

Publications

  • Jensen KJ, Sondergaard M, Andersen A, Sartono E, Martins C, Garly ML, Eugen-Olsen J, Ullum H, Yazdanbakhsh M, Aaby P, Benn CS, Erikstrup C. A randomized trial of an early measles vaccine at 4(1/2) months of age in Guinea-Bissau: sex-differential immunological effects. PLoS One. 2014 May 16;9(5):e97536. doi: 10.1371/journal.pone.0097536. eCollection 2014.

    PubMed 24835247

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Measles vaccine in people with Measles and Diphtheria, run by Bandim Health Project at 1 site in Guinea-Bissau.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Guinea-Bissau. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cytokine levels in the randomised groups. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00168545, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2011.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in